BioCentury
ARTICLE | Clinical News

Genentech reports Phase II data of polatuzumab vedotin in DLBCL

December 1, 2017 9:40 PM UTC

In an abstract released ahead of the American Society of Hematology (ASH) meeting, the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported data from 80 evaluable patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) from the Phase II portion of a Phase Ib/II trial of polatuzumab vedotin plus Treanda bendamustine and Rituxan rituximab. Specifically, the combination led to a best overall response rate (ORR) of 70%, including 23 complete responses and 5 partial responses vs. 33% for Treanda and Rituxan alone, including 8 complete responses and 5 partial responses. There was 1 case of stable disease for polatuzumab vedotin plus Treanda and Rituxan, and 2 cases of stable disease for Treanda and Rituxan alone. The polatuzumab vedotin combo also led to a 48% ORR at the primary response assessment at 6-8 weeks after last treatment, including 17 complete responses and 2 partial responses vs. 18% for Treanda and Rituxan alone, including 6 complete responses and 1 partial response, plus 1 case of stable disease.

The median duration of response was 8.8 months in the polatuzumab vedotin combo arm vs. 3.7 months for Treanda and Rituxan alone. Additionally, polatuzumab vedotin plus Treanda and Rituxan led to a median progression-free survival (PFS) of 6.7 months (p<0.0001) and and an overall survival (OS) of 11.8 months (p=0.0008) vs. 2 and 4.7 months, respectively, for Treanda and Rituxan alone...